4-羟基丁酸钠
4-羟基丁酸钠结构式
|
常用名 | 4-羟基丁酸钠 | 英文名 | 4-Hydroxybutanoic acid sodium salt |
|---|---|---|---|---|
| CAS号 | 502-85-2 | 分子量 | 126.086 | |
| 密度 | N/A | 沸点 | 295.6ºC at 760mmHg | |
| 分子式 | C4H8NaO3+ | 熔点 | 145-146ºC | |
| MSDS | N/A | 闪点 | 146.8ºC | |
| 符号 |
GHS02, GHS06, GHS08 |
信号词 | Danger |
4-羟基丁酸钠用途【用途一】 全身麻醉药。适用于神经外科、妇产科、整形外科、头颈及四肢部们的外科物术等。 |
| 中文名 | 4-羟基丁酸钠 |
|---|---|
| 英文名 | .γ.-Hydroxybutyric acid monosodium salt |
| 中文别名 | 羟丁酸钠 |
| 英文别名 | 更多 |
| 沸点 | 295.6ºC at 760mmHg |
|---|---|
| 熔点 | 145-146ºC |
| 分子式 | C4H8NaO3+ |
| 分子量 | 126.086 |
| 闪点 | 146.8ºC |
| 精确质量 | 126.029289 |
| PSA | 57.53000 |
| 储存条件 | Controlled Substance, -20?C Freezer |
| 符号 |
GHS02, GHS06, GHS08 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H225-H301 + H311 + H331-H370 |
| 警示性声明 | P210-P260-P280-P301 + P310-P311 |
| 危害码 (欧洲) | F,T |
| 风险声明 (欧洲) | 11-23/24/25-39/23/24/25 |
| 安全声明 (欧洲) | S24/25 |
| 危险品运输编码 | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK德国 | 2 |
| RTECS号 | ET4750000 |
| 海关编码 | 2918199090 |
|
~93%
4-羟基丁酸钠 502-85-2 |
| 文献：Organic and Biomolecular Chemistry, , vol. 10, # 47 p. 9418 - 9428 |
|
~%
4-羟基丁酸钠 502-85-2 |
| 文献：Journal of the American Chemical Society, , vol. 52, p. 3702 |
CAS号26976-72-7
CAS号591-81-1
CAS号10385-30-5![4-[bis(4-methoxyphenyl)-phenylmethoxy]butanoic acid结构式](https://image.chemsrc.com/caspic/340/150907-74-7.png)
CAS号150907-74-7
CAS号91970-62-6
CAS号925-57-5由γ-丁内酸开环而得。将氢氧化钠在搅拌下溶于水中，于50-60℃滴加γ-丁内酯，加毕，继续保温搅拌2h，加活性炭脱色40min，过滤，滤液减压深缩至干，加乙醇搅拌成浆状，过滤，用少量乙醇洗涤，80℃以下干燥，得γ-羟基丁酸钠。收率90%。
| 海关编码 | 2918199090 |
|---|---|
| 中文概述 | HS: 2918199090. 其他含醇基但不含其他含氧基羧酸（包括其酸酐、酰卤化物、过氧化物和过氧酸及该税号的衍生物）. 增值税率:17.0%. 退税率:9.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0% |
| 申报要素 | 品名, 成分含量, 用途 |
| Summary | 2918199090 other carboxylic acids with alcohol function but without other oxygen function, their anhydrides, halides, peroxides, peroxyacids and their derivatives。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:30.0% |
|
An improved design of water-soluble propofol prodrugs characterized by rapid onset of action.
Anesth. Analg. 118(4) , 745-54, (2014) Phosphate ester prodrugs of propofol (fospropofol, HX0969W) were designed to avoid the unsatisfactory water solubility of the parent drug. However, in previous clinical trials, there were reported pro... |
|
|
Treatment of alcohol dependence: recent progress and reduction of consumption.
Minerva Med. 105(6) , 447-66, (2014) Alcohol dependence (AD) is a major public health problem. Currently, three drugs for the treatment of AD have been approved by both the European Medicines Agency (EMA) and the Food and Drug Administra... |
|
|
Discriminative stimulus effects of the GABAB receptor-positive modulator rac-BHFF: comparison with GABAB receptor agonists and drugs of abuse.
J. Pharmacol. Exp. Ther. 344(3) , 553-60, (2013) GABA(B) receptor-positive modulators are thought to have advantages as potential medications for anxiety, depression, and drug addiction. They may have fewer side effects than GABA(B) receptor agonist... |
| GHB |
| Sodium 4-hydroxybutanoate |
| Xyrem |
| 4-Hydroxybutyrate sodium |
| Butanoic acid, 4-hydroxy-, sodium salt (1:1) |
| Sodium Oxybate |
| GHB SODIUM SALT |
| Butanoic acid, 4-hydroxy-, monosodium salt |
| Butanoic acid, 4-hydroxy-, sodium salt |
| gammaoh |
| MFCD00004402 |
| γ-OH |
| SODIUM 4-HYDROXYBUTYRATE |
| γ-Hydroxybutyrate sodium |
| wy-3478 |
| 4-Hydroxybutanoic Acid Monosodium Salt |
| 4-Hydroxybutyric acid monosodium salt |
| Sodium γ-hydroxybutyrate |
| Butyric acid, 4-hydroxy-, monosodium salt (8CI) |
| somsanit |
| γ-Hydroxybutyric acid monosodium salt |
| Butyric acid, 4-hydroxy-, sodium salt |
| Butyric acid, 4-hydroxy-, monosodium salt |
| Sodium Oxybate [USAN] |
| 4-Hydroxybutyric acid sodium salt |
| EINECS 207-953-3 |
